News ArchivesRead News

Your Parkinson's News Update for the Week of 5.11.20

Monday May 11, 2020
New Trial Platform Could Accelerate
Finding a Cure for Parkinson's
Journal of Parkinson's Disease via MedicalXpress
Researchers report on the possibility of using a multi-arm, multi-stage (MAMS) trial platform to evaluate several potential therapies at once, using lessons learned from other diseases.
"The current way we do trials in Parkinson's is too slow and inefficient," explained lead author Camille Buchholz Carroll, MD, Ph.D., Applied Parkinson's Research Group, University of Plymouth, Faculty of Health, Plymouth, UK. "We need to develop new ways of doing trials such as the MAMS trial platform, which will speed up the process and bring us closer to finding a cure, faster. We have the opportunity to learn from the experience in these other conditions and design a new trial that will work for people with Parkinson's."
Pass-to-Pass on the Pacific Crest Trail
The Outdoor Evolution
“Doctor, let me get this straight. You’re telling me, a seventy-year-old guy with gait and balance issues combined with tremors in both arms and hands, to go on a sixty-mile nine-day backpack adventure on the Pacific Crest Trail? And you think it’s going to be fun?”
That was my introduction to Pass to Pass on the Pacific Crest Trail. My neurologist was convinced it would be to my benefit and urged me to accept the challenge. It includes all aspects of positive activity for people with Parkinson’s disease: cognitive, physical, and social.
Predictive Models Could Provide More Accurate
Detection of Early-Stage Parkinson's
Frontiers in Neurology via Medical Xpress
Neuroscientists at York University have found five different models that use these types of non-motor clinical as well as biological variables to more accurately predict early-stage Parkinson's.
"Right now, there's no cure for Parkinson's. All we know now are the signs and symptoms and we can only treat the symptoms," stated one of the study's researchers. "These models could be very useful in differentiating patients who may present with Parkinson's-like symptoms not related to Parkinson's pathology from patients who actually have [Parkinson's]."